IL163960A0 - Broadspectrum subsituted benzimidazole sulfonamidehiv protease inhibitors - Google Patents

Broadspectrum subsituted benzimidazole sulfonamidehiv protease inhibitors

Info

Publication number
IL163960A0
IL163960A0 IL16396003A IL16396003A IL163960A0 IL 163960 A0 IL163960 A0 IL 163960A0 IL 16396003 A IL16396003 A IL 16396003A IL 16396003 A IL16396003 A IL 16396003A IL 163960 A0 IL163960 A0 IL 163960A0
Authority
IL
Israel
Prior art keywords
sulfonamidehiv
broadspectrum
subsituted
benzimidazole
protease inhibitors
Prior art date
Application number
IL16396003A
Other languages
English (en)
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of IL163960A0 publication Critical patent/IL163960A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL16396003A 2002-03-12 2003-03-12 Broadspectrum subsituted benzimidazole sulfonamidehiv protease inhibitors IL163960A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075999 2002-03-12
PCT/EP2003/050057 WO2003076413A1 (en) 2002-03-12 2003-03-12 Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors

Publications (1)

Publication Number Publication Date
IL163960A0 true IL163960A0 (en) 2005-12-18

Family

ID=27798870

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16396003A IL163960A0 (en) 2002-03-12 2003-03-12 Broadspectrum subsituted benzimidazole sulfonamidehiv protease inhibitors

Country Status (26)

Country Link
US (2) US20050171175A1 (es)
EP (1) EP1485358B1 (es)
JP (1) JP4557552B2 (es)
KR (3) KR20120136411A (es)
CN (2) CN1653053A (es)
AP (1) AP2111A (es)
AR (1) AR038928A1 (es)
AT (1) ATE497494T1 (es)
AU (1) AU2003219159B2 (es)
BR (1) BR0303373A (es)
CA (1) CA2479012C (es)
DE (1) DE60335939D1 (es)
DK (1) DK1485358T3 (es)
EA (1) EA011946B1 (es)
HK (1) HK1072053A1 (es)
HR (1) HRP20040936B1 (es)
IL (1) IL163960A0 (es)
MX (1) MXPA04008929A (es)
MY (1) MY142238A (es)
NO (1) NO326702B1 (es)
NZ (1) NZ535439A (es)
PL (1) PL213645B1 (es)
SI (1) SI1485358T1 (es)
TW (1) TWI329639B (es)
WO (1) WO2003076413A1 (es)
ZA (1) ZA200407242B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4919802B2 (ja) * 2003-09-30 2012-04-18 テイボテク・フアーマシユーチカルズ ベンゾオキサゾールスルホンアミド化合物およびその中間体の製造方法
EP2422781A1 (en) * 2004-05-07 2012-02-29 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
DK1856125T3 (da) 2005-02-25 2009-12-07 Tibotec Pharm Ltd Syntese af proteasehæmmerforstadie
UA103013C2 (uk) 2007-12-06 2013-09-10 Тиботек Фармасьютикелз Амідні сполуки як активатори противірусних препаратів
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
WO2013011485A1 (en) * 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE69321845T2 (de) * 1992-08-25 1999-04-29 Monsanto Co Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
ES2127938T3 (es) 1993-08-24 1999-05-01 Searle & Co Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas.
SG48049A1 (en) 1993-10-01 1998-04-17 Astra Ab Process i
US6143747A (en) * 1995-01-20 2000-11-07 G. D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6140505A (en) * 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
JP4124818B2 (ja) * 1995-03-10 2008-07-23 ジー．ディー．サール アンド カンパニー ヘテロシクロカルボニルアミノ酸ヒドロキシエチルアミノスルホンアミドレトロウイルスプロテアーゼインヒビター
US5776971A (en) * 1995-03-10 1998-07-07 G.D. Searle & Co. Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
AU7722296A (en) 1995-11-15 1997-06-05 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
EA001219B1 (ru) 1996-05-20 2000-12-25 Жансен Фармасетика Н.В. Антигрибковые композиции с улучшенной биологической доступностью
KR100520936B1 (ko) 1997-03-26 2005-10-17 얀센 파마슈티카 엔.브이. 항진균제 및 중합체로 코팅된 코어를 갖는 펠릿제
JP2002501721A (ja) * 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
HUP0101598A3 (en) 1997-12-24 2002-08-28 Vertex Pharmaceuticals Inc Cam Prodrugs of aspartyl protease inhibitors and medicaments containing them
PT1086076E (pt) * 1998-06-19 2005-05-31 Vertex Pharma Inibidores de sulfonamida de aspartil protease
WO1999067254A2 (en) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion

Also Published As

Publication number Publication date
AP2111A (en) 2010-03-03
HRP20040936B1 (en) 2012-09-30
HK1072053A1 (en) 2005-08-12
DE60335939D1 (de) 2011-03-17
ATE497494T1 (de) 2011-02-15
ZA200407242B (en) 2005-12-28
EP1485358B1 (en) 2011-02-02
US20090203743A1 (en) 2009-08-13
JP4557552B2 (ja) 2010-10-06
TW200400945A (en) 2004-01-16
HRP20040936A2 (en) 2005-10-31
CA2479012A1 (en) 2003-09-18
AR038928A1 (es) 2005-02-02
AU2003219159A1 (en) 2003-09-22
EA200401188A1 (ru) 2005-04-28
BR0303373A (pt) 2004-03-23
CN101935303A (zh) 2011-01-05
DK1485358T3 (da) 2011-05-09
TWI329639B (en) 2010-09-01
AP2004003151A0 (en) 2004-12-31
PL374152A1 (en) 2005-10-03
PL213645B1 (pl) 2013-04-30
SI1485358T1 (sl) 2011-05-31
AU2003219159B2 (en) 2009-09-03
MY142238A (en) 2010-11-15
KR20120136411A (ko) 2012-12-18
NZ535439A (en) 2009-09-25
EA011946B1 (ru) 2009-06-30
CA2479012C (en) 2011-11-01
MXPA04008929A (es) 2004-11-26
CN101935303B (zh) 2014-03-12
JP2005519952A (ja) 2005-07-07
NO20035023D0 (no) 2003-11-12
KR20040093119A (ko) 2004-11-04
WO2003076413A1 (en) 2003-09-18
US8143421B2 (en) 2012-03-27
KR101302421B1 (ko) 2013-09-02
KR20100102742A (ko) 2010-09-24
EP1485358A1 (en) 2004-12-15
NO326702B1 (no) 2009-02-02
US20050171175A1 (en) 2005-08-04
CN1653053A (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
EP1499336A4 (en) PROTEASE INHIBITORS
ZA200604833B (en) Heterocyclic aspartyl protease inhibitors
EP1483254A4 (en) INHIBITORS OF ANTI-RESISTANCE RETROVIRAL PROTEASE
EP1569633A4 (en) CA-IX SPECIFIC HEMMER
IL166257A0 (en) Broadspectrum 2-amino-benzothiazole sulfonamide HIV protease inhibitors
IL166462A0 (en) Broadspectrum substituted oxindole sulfonamide hivproteases inhibitors
HK1076099A1 (en) Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
EP1663279A4 (en) MODIFIED PROTEASE INHIBITORS
EP1704142A4 (en) PROTEASE INHIBITORS
HK1072053A1 (en) Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
IL164898A0 (en) Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors
AU2003249540A8 (en) Fused bicyclic metalloproteinase inhibitors
AU2003269984A8 (en) Protease inhibitors
EP1531857A4 (en) Metalloproteinase inhibitors
AU2003263738A8 (en) Protease inhibitors
ZA200500926B (en) Broadspectrum 2-amino-benzothiazole sulfonamide HIV protease inhibitors
AU2003304496A8 (en) Protease inhibitors
AU2003233642A8 (en) Protease inhibitors
AU2003269878A8 (en) Protease inhibitors
AU2003265240A8 (en) Protease inhibitors
AU2003298513A8 (en) Sterically-awkward beta-lactamase inhibitors